Integra LifeSciences (NASDAQ:IART) Stock Price Down 4.4% - Should You Sell?

Integra LifeSciences Holdings Corporation (NASDAQ:IART - Get Free Report) shares fell 4.4% during mid-day trading on Friday . The company traded as low as $11.46 and last traded at $11.46. 171,604 shares traded hands during mid-day trading, a decline of 82% from the average session volume of 969,890 shares. The stock had previously closed at $11.98.

Analysts Set New Price Targets

A number of research analysts have weighed in on IART shares. JMP Securities reduced their price target on shares of Integra LifeSciences from $35.00 to $25.00 and set a "market outperform" rating on the stock in a research report on Friday, May 9th. Wells Fargo & Company cut their price target on shares of Integra LifeSciences from $25.00 to $13.00 and set an "equal weight" rating for the company in a report on Tuesday, May 6th. JPMorgan Chase & Co. reduced their price objective on shares of Integra LifeSciences from $24.00 to $12.00 and set an "underweight" rating for the company in a research note on Tuesday, May 6th. Truist Financial dropped their target price on Integra LifeSciences from $26.00 to $19.00 and set a "hold" rating on the stock in a report on Friday, April 11th. Finally, Argus upgraded Integra LifeSciences from a "hold" rating to a "buy" rating in a report on Monday, March 31st. Four investment analysts have rated the stock with a sell rating, three have given a hold rating and two have given a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus target price of $18.63.

Integra LifeSciences Stock Up 6.5%

The company has a quick ratio of 0.72, a current ratio of 1.21 and a debt-to-equity ratio of 0.81. The company has a fifty day moving average price of $12.70 and a 200-day moving average price of $18.28. The stock has a market capitalization of $941.30 million, a P/E ratio of -31.88, a PEG ratio of 0.62 and a beta of 1.15.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last posted its earnings results on Monday, May 5th. The life sciences company reported $0.41 earnings per share for the quarter, missing analysts' consensus estimates of $0.43 by ($0.02). Integra LifeSciences had a positive return on equity of 12.12% and a negative net margin of 1.78%. The company had revenue of $382.65 million for the quarter, compared to analysts' expectations of $381.17 million. During the same quarter in the prior year, the company earned $0.55 EPS. The firm's quarterly revenue was up 3.7% on a year-over-year basis. As a group, research analysts forecast that Integra LifeSciences Holdings Corporation will post 2.45 EPS for the current fiscal year.

Institutional Investors Weigh In On Integra LifeSciences

Large investors have recently made changes to their positions in the stock. Arizona State Retirement System lifted its position in shares of Integra LifeSciences by 4.2% during the 1st quarter. Arizona State Retirement System now owns 19,894 shares of the life sciences company's stock worth $437,000 after purchasing an additional 795 shares during the last quarter. Wedge Capital Management L L P NC grew its position in Integra LifeSciences by 1.2% during the second quarter. Wedge Capital Management L L P NC now owns 70,114 shares of the life sciences company's stock worth $860,000 after buying an additional 801 shares during the period. Arrowstreet Capital Limited Partnership lifted its holdings in shares of Integra LifeSciences by 7.1% in the fourth quarter. Arrowstreet Capital Limited Partnership now owns 13,756 shares of the life sciences company's stock valued at $312,000 after purchasing an additional 913 shares in the last quarter. Envestnet Asset Management Inc. lifted its holdings in shares of Integra LifeSciences by 4.6% in the first quarter. Envestnet Asset Management Inc. now owns 27,527 shares of the life sciences company's stock valued at $605,000 after purchasing an additional 1,204 shares in the last quarter. Finally, Quadrant Capital Group LLC lifted its stake in shares of Integra LifeSciences by 5,960.9% during the fourth quarter. Quadrant Capital Group LLC now owns 1,394 shares of the life sciences company's stock valued at $32,000 after buying an additional 1,371 shares during the period. 84.78% of the stock is currently owned by hedge funds and other institutional investors.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.